P210011/S006: xT CDx
FDA’s recorded scope: approval of component changes.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 4 FDA records to the applicant name Tempus AI, Inc.. The collection includes 1 510(k) clearance. It includes 1 original PMA approval. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Apr 28, 2023 to Oct 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code PQP appears in 3 of the 4 linked filings. The collection spans 2 FDA product codes and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P210011, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 600 W Chicago Ave., Suite #510, Chicago, IL, 60654. Recorded on P210011/S006, decision dated Oct 23, 2026.
Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System; Atrial Fibrillation Risk Prediction Machine Learning-Based Notification Software.
FDA’s recorded scope: approval of component changes.
Supplement S002 to PMA P210011 covers a pre-specified change control plan (PCCP) that would modify use of the device from a single laboratory to multiple laboratories. The listed supplement reason is change in design, components, specifications or material, on the normal 180-day track. The device category is a next generation sequencing oncology panel, somatic or germline variant detection system, in pathology under product code PQP, filed by Tempus AI, Inc.
The source field states approval of the PCCP for that scope change, but does not identify the components or specifications altered, the number or identity of additional laboratories, or supporting data. The statement's purpose is not independent evidence of analytical or clinical performance, and it does not extend the original PMA to new indications.
Approval for a Pre-specified Change Control Plan (PCCP) to modify the use of the device at a single laboratory to multiple laboratories
The FDA record for P210011 lists an approval decision dated 2023-04-28 for xT CDx, a qualitative NGS-based in vitro diagnostic device. Per the source statement, it detects substitutions (SNVs and MNVs) and INDELs in 648 genes, plus microsatellite instability status, using DNA from FFPE tumor tissue and from matched normal blood or saliva, in previously diagnosed cancer patients with solid malignant neoplasms.
The stated intended uses include companion diagnostic identification of patients who may benefit from therapies listed in the Companion Diagnostic Indications table per approved therapeutic labeling, and tumor mutation profiling by qualified health care professionals per oncology professional guidelines. The statement says genomic findings outside that table are not prescriptive or conclusive for labeled use of any specific therapeutic product, and that xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL. The record carries no supplement type or reason, so the original scope is described rather than a changed item. These are reported intended uses, not independent proof of safety or clinical effectiveness.
Approval for the xT CDx. The device is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms.The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling.Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Tempus ECG-MRK254297 | Tempus AI, Inc. | 510(k) clearance | Sep 25, 2026 | FDA |
xT CDxP210011/S002 | Tempus AI, Inc. | PMA supplement | Sep 2, 2026 | FDA |
xT CDxP210011 | Tempus AI, Inc. | PMA approval | Apr 28, 2023 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 19, 2026.